Inhibrx — Investor Presentation (January 2022)
41 slides from Inhibrx's investor presentation, Jan 4, 2022
Slide 1: Outcomes Focused Innovation Driven January 2022
Outcomes Focused Innovation Driven January 2022
Slide 2: Forward-looking statements
2 This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminol
Slide 3: Four differentiated clinical programs
3 Four differentiated clinical programs INBRX-109 Tetravalent DR5 agonist + Single agent activity in chondrosarcoma and mesothelioma + Potential rapid path to approval in chondrosarcoma, registration study initiated + First combination cohorts: mesothelioma, pancreatic adenocarcinoma, colorectal can
Slide 4: Why invest in Inhibrx?
4 Why invest in Inhibrx? Backed by solid institutional investor base with substantial internal ownership Four differentiated clinical programs with value-creating readouts in 2022/2023 KEY FINANCIAL HIGHLIGHTS* 38.9M $141.1M 43.1MRobust emerging pre-clinical pipeline Potential to reach financial sus
Slide 5: Inhibrx at a glance
5 Inhibrx at a glance + Experienced leadership team + Proven innovation and execution VALIDATION FROM INDUSTRY LEADING PARTNERS All platforms and programs developed in-house with strong patent protection Inhibrx’s modular sdAb platform + Ability to precision engineer to specific target biology + Sma
Slide 6: INBRX-106 Hexavalent OX40 Agonist
INBRX-106 Hexavalent OX40 Agonist
Slide 7: Hexavalent OX40 agonist
7 Hexavalent OX40 agonist OX40 is a co-stimulatory receptor on activated T-cells: + Provides co-stimulation to activated T-cells + Reverses regulatory T-cell induced immune suppression + Enhances T-cell functionality + Additional benefit in combination with PD-1 blockade OX40: sdAb OX40: sdAb OX40:
Slide 8: INBRX-106 is a best-in-class OX40 agonist
8 INBRX-106 is a best-in-class OX40 agonist CANDIDATES VALENCY ISOTYPE LIGAND BLOCKING STATUS INBRX-106 Hex- IgG1 N Ph 1 (2019) MOXR-0916 Bi- IgG1 Y Discontinued GSK-3174998 Discontinued BMS-986178 Ph 1 (2016) INCAGN-1949 Ph 1 (2016) ABBV-368 Ph 1 (HNSCC, 2020) IBI-101 Ph 1 (2018) MEDI-0562 Disconti
Slide 9: INBRX-106 Phase 1 in combination with Keytruda
9 Complete PART 3 + Five response evaluable patients with tumor types responsive to immunotherapy in the active dose range: o Two durable PRs > 6 months and treatment ongoing (nasopharyngeal carcinoma and uveal melanoma CPI-naïve) o One double-digit reduction in tumor volume with duration >4 months
Slide 10: INBRX-106 Phase 1 single agent activity
10 Complete INBRX-106 Phase 1 single agent activity Complete Dose escalation Dose expansion PART 1 + 4/10 response evaluable NSCLC & melanoma patients with duration greater than 6 months (three CPI-exposed patients and one CPI-naïve uveal melanoma patient) + Longest duration to date as of January 4,
Slide 11: Market opportunity
11 Market opportunity The figures on this slide represent market research estimates from Evaluate Pharma *Keytruda™ and Opdivo® go off patent in 2028 $14.4 $7.9 $2.9 $2.0 $1.0 $28.2$27.1 $14.2 $7.4 $4.7 $10.1 $63.5 $0 $10 $20 $30 $40 $50 $60 $70 KEYTRUDA* OPDIVO* TECENTRIQ IMFINZI OTHER TOTAL 2020 P
Slide 12: INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein
INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein AAT Fc
Slide 13: Alpha-1 antitrypsin deficiency (AATD)
13 Alpha-1 antitrypsin deficiency (AATD) Disease overview + AATD is an inherited orphan respiratory disease characterized by deficient levels of alpha-1 antitrypsin (AAT) causing loss of lung function and decreased life expectancy + A small percentage of patients also develop liver disease Current s
Slide 14: Potential advantages of recombinant AAT Fc-fusion protein INBRX-101
14 Potential advantages of recombinant AAT Fc-fusion protein INBRX-101 Potential advantages of INBRX-101 Potential to extend the dosing interval from weekly to monthly Goal is to maintain patients in the normal serum range of AAT and to normalize the functional activity of AAT Recombinant manufactur
Slide 15: Competitive comparison
15 THERAPIES Plasma-Derived AAT Aralast Glassia Prolastin-C Zemaira Inhaled AAT Oral Neutrophil Elastase Inhibitor Alvelestat Small Molecule Corrector ZF874 Competitive comparison Applicable to all patients THERAPIES ARO-AAT DCR-A1AT 15%100% Applicable to ~15% of patients with liver issues
Slide 16: INBRX-101 - Initial results from Phase 1, Part 1
16 INBRX-101 - Initial results from Phase 1, Part 1 N=24 Complete N=6 10 mg/kg N=6 40 mg/kg N=6 120 mg/kg N=6 80 mg/kg Single ascending dose escalation (SAD) PART 1 + Favorable safety and tolerability profile with no drug-related SAEs at doses up to and including 120 mg/kg SAD and 80 mg/kg MAD + Dos
Slide 17: INBRX-101 - Initial results from Phase 1, Part 2
17 Complete Initiated Remainder of Phase 1, Part 2 expected H1 2022 INBRX-101 - Initial results from Phase 1, Part 2 - 40 mg/kg N=18 * bronchoalveolar lavage N=6 40 mg/kg N=6 80 mg/kg* N=6 120 mg/kg* INBRX-101 Initial Results - 40 mg/kg (Q3W) Initial data from 40 mg/kg predicts a dose of 80-120 mg/k
Slide 18: INBRX-109 Tetravalent DR5 Agonist
INBRX-109 Tetravalent DR5 Agonist
Slide 19: Tetravalent DR5 agonist
19 Tetravalent DR5 agonist + Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) + DR5 activation naturally eliminates damaged and neoplastic cells DR5: sdAb DR5: sdAbDR5: sdAb DR5: sdAb 105 kDa Fc: effector function disabled
Slide 20: INBRX-109 is a best-in-class DR5 agonist
20 INBRX-109 is a best-in-class DR5 agonist CANDIDATE VALENCY SIZE (KDA) INBRX-109 Tetravalent 105 TAS-266 Tetravalent 60 Eftozanermin alpha (TRAIL-Fc fusion) Hexavalent 167 GEN10292 Dodecavalent 150 ka (2x mAbs) IGM-8444 Decavalent3 ~950 Dulanermin (recombinant TRAIL) Trivalent 150 Tigatuzumab Biva
Slide 21: Fast to market opportunity
21 Fast to market opportunity ~1,400 cases per year Incidence rate of ~1 in 200,000 persons per year USA Worldwide Chondrosarcoma *The figures on this slide represent market research estimates. No approved therapeutic for the treatment of chondrosarcoma Therapeutic IPI-926 (HH) Control arm Placebo S
Slide 22: Phase 1 data in unresectable or metastatic conventional chondrosarcoma
22 Best Response 3mo 4mo 6mo 9mo 12mo SD (-20%) 77wks SD (-11%) 64wks SD (-7%) 62wks PR (-61%) SD (-13%) SD (+3%) PR (-32%) SD (-4%) ** SD (-1%) ► SD (-3%) SD (-20%) ► SD (+5%) SD (+3%) * SD (-5%) * SD (+5%) SD (+7%) PD (+31%) PD (+16%) Pending ► Pending ► Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1
Slide 23: INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma
23 Endpoints Primary: Progression free survival Secondary: Overall survival, overall response rate, duration of response, disease control rate, quality of life INBRX-109 Phase 2 registration-enabling study design in chondrosarcoma Randomization Conventional chondrosarcoma, grade 2 and 3, unresectabl
Slide 24: Phase 1 data in malignant pleural mesothelioma
24 Best Response 3mo 4mo 6mo 9mo SD (-24%) * SD (-17%) SD (-12%) PR (-100%) SD (-22%) SD (-20%) sd (-12%) SD (-5%) SD (-2%) SD (+9%) SD (+13%) SD (+16%) SD (+1%) * PD PD PD PD (+25%) PD (+33%) PD (+33%) Weeks 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 3
Slide 25: INBRX-109 on the horizon
25 Initiated Ongoing FUTURE POTENTIAL OPPORTUNITIES Solid tumors + IAP antagonists Hematologic tumors + Bcl-2 inhibitors NSCLC + various combo agents Gastric and colon cancer + various combo agents Additional sarcoma indications INBRX-109 on the horizon Combination studies Pancreatic adenocarcinoma
Slide 26: INBRX-105 PD-L1 x 4-1BB Multispecific
INBRX-105 PD-L1 x 4-1BB Multispecific
Slide 27: PD-L1 x 4-1BB multispecific
27 PD-L1 x 4-1BB multispecific + Designed to provide spatially-restricted 4-1BB agonism at sites of PD-L1 expression + Highly expressed on tumor infiltrating immune cells, 4-1BB signaling promotes prolonged T-cell survival memory formation + Constitutive 4-1BB agonism has achieved anti-tumor respons
Slide 28: INBRX-105 is a best-in-class 4-1BB agonist
28 INBRX-105 is a best-in-class 4-1BB agonist CANDIDATE FORMAT 4-1BBL BLOCKING INBRX-105 Bivalent/Bivalent No Gen-1064 Monovalent/Monovalent n/a MCLA-145 Monovalent/Monovalent Yes FS222 Bivalent/Bivalent n/a PRS-343 Bivalent/Bivalent No ND021 Monovalent/Monovalent n/a CANDIDATE IGG SUBCLASS 4-1BBL B
Slide 29: INBRX-105 Phase 1 trial design
29 PlannedInitiatedOngoingComplete INBRX-105 Phase 1 trial design Single agent: PD-L1+ Basket Single agent dose escalation Single agent dose expansion N=80N=32 N=12N=32 No pre-screening, all-comers + 8/18 (44%) at dose levels ≥ 0.1 mg/kg achieved stable disease + Patients were not pre-screened for P
Slide 30: Molecular Targeted Cytokine (MTC) Platform
Molecular Targeted Cytokine (MTC) Platform A Targeted Detuned IL-2 Platform
Slide 31: Affinity differential enables directed IL-2 expansion
31 Affinity differential enables directed IL-2 expansion/enhancement of specific cell types High affinity antibody targeting INHIBRX has developed sdAbs to an extensive number of antigens + T-cell or NK cell subsets + Activating/co-stimulatory receptors + Inhibitory receptors + Exhaustion markers Pr
Slide 32: INBRX-121 NKp46 Targeted Detuned IL-2
INBRX-121 NKp46 Targeted Detuned IL-2
Slide 33: INBRX-121 expands the NK cell population and enhances cytotoxicity
33 INBRX-121 expands the NK cell population and enhances cytotoxicity + NKp46 is an NK-specific marker that maintains expression on tumor-infiltrating NK cells + Proprietary IL2-X engineering ensures specific modulation of NK Cells without impacting T-cell subsets (Tcon and Treg) NKp46 sdAb NKp46 sd
Slide 34: INBRX-121 is poised to bring NK cells to the forefront of immunotherapy
34 INBRX-121 INBRX-121 is poised to bring NK cells to the forefront of immunotherapy NK NK NK NK NK NK NK NK NK NK Improved NK Activity Safety with durability Multiple paths forward Single agent Activated NK cells exhibit immediate cytotoxicity Combination therapy Enhances the activity of therapeuti
Slide 35: Expands mouse NK cells and enhances their cytotoxic potential
35 Expands mouse NK cells and enhances their cytotoxic potential 0 2,000 3,000 4,000 5,000 KL RG 1 le ve ls 5,000 10,000 15,000 20,000 Gr an zy m e B le ve ls M ax . f ol d- ch an ge (r el at iv e to v eh ic le ) 0 5 10 20 25 15 NK cells CD8 T cells Tregs CD4+Tcon B cells NK cell cytolytic activityN
Slide 36: Synergizes with approved therapeutic antibodies
36 Synergizes with approved therapeutic antibodies INBRX-121 synergizes with Rituxan® in a subcutaneous Raji tumor model resulting in complete tumor regression Dosing Days TREATMENT COMPLETE RESPONSES Rituxan® 0/10 INBRX-121 + Rituxan® 9/10 Raji tumor growth 0 42 Time (days) 0 Tu m or Vo lu m e (m m
Slide 37: INBRX-121 safely expands NK cells in non-human primates
37 INBRX-121 safely expands NK cells in non-human primates 8% 82% 10% 41.5% 51.5% 7% Expands NK cells in a dose-dependent manner (up to 12-fold) that persists for more than 21 days and can be dosed multiple times safely Tolerated at all tested doses (up to 30 mg/kg) with no clinical signs of toxicit
Slide 38: Expands NK cells from Lymphoma patients
38 Expands NK cells from Lymphoma patients NK cells from Lymphoma patients express NKp46 at levels similar or above that of healthy donors Patient NK cells respond to stimulation with INBRX-121 by upregulating pSTAT5 and show an increased proliferative potential - + Healthy Donor 0 20 40 % p ST AT 5
Slide 39: Expands the number of NK cells while enhancing their cytotoxic capacities
39 Expands the number of NK cells while enhancing their individual cytotoxic capacities INBRX-121 increases NK cell-mediated killing of Raji cells in the presence of a Rituximab sequence analog (Anti-hCD20- hIgG1). Raji cell killing after INBRX-121 pre-incubation Effector: target ratio 0 % Ta rge t
Slide 40: Near term expected clinical milestones
40 Near term expected clinical milestones H1 2022 H2 2022 (OX40) / Keytruda dose expansion cohort data (AAT) Additional Phase 1 data (PD-L1 x 41BB) Keytruda dose escalation data (PD-L1 x 41BB) Keytruda dose expansion cohort data (DR5) Initial mesothelioma, Ewing sarcoma, pancreatic, and colorectal c
Slide 41: Contact: La Jolla, CA, www.inhibrx.com
11025 N. Torrey Pines Rd Ste 200 La Jolla, CA 92037 www.inhibrx.com